In this study we analyze the major clinical trials of immunotherapy for solid tumors. Much progress have been made in reducing the side effects and the percentage of patients which respond has increased. In immunotherapy with lymphokines the innovative orientation consist in the administration of low doses or decreasing doses and by alternative ways as regards infusion and systemically. The use of immunotherapy to stimulate the specific immune response seems to represent the most promising field from a therapeutic point of view. Studies in the field of in vitro expansion of immunocompetent cells have obtained results in the simplification of the technique and in an increase of its efficiency; moreover, at the moment, many clinical trials are involving specific immunotherapy using autologous neoplastic cells altered with adjuvant substance and the results are promising with very few side effects. In the near future immunotherapy with specific tumor antigens is sure it will play a major role.